WO2002078672A3 - Liposomal tumor necrosis factor compositions and methods - Google Patents

Liposomal tumor necrosis factor compositions and methods Download PDF

Info

Publication number
WO2002078672A3
WO2002078672A3 PCT/US2002/009926 US0209926W WO02078672A3 WO 2002078672 A3 WO2002078672 A3 WO 2002078672A3 US 0209926 W US0209926 W US 0209926W WO 02078672 A3 WO02078672 A3 WO 02078672A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
necrosis factor
tumor necrosis
factor compositions
liposomal
Prior art date
Application number
PCT/US2002/009926
Other languages
French (fr)
Other versions
WO2002078672A2 (en
Inventor
Daila S Gridley
Dong W Kim
Hagen Timo L Ten
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of WO2002078672A2 publication Critical patent/WO2002078672A2/en
Publication of WO2002078672A3 publication Critical patent/WO2002078672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Abstract

Liposome compositions containing an entrapped TNF compound and a method of using the same for effective upregulation of immunological factors are described. Also disclosed is a method of combination therapy where a conventional anti-tumor therapy and the liposome-entrapped TNF compound are administered to achieve an enhanced anti-tumor effect.
PCT/US2002/009926 2001-03-30 2002-03-29 Liposomal tumor necrosis factor compositions and methods WO2002078672A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28054001P 2001-03-30 2001-03-30
US60/280,540 2001-03-30
US34300201P 2001-12-19 2001-12-19
US60/343,002 2001-12-19

Publications (2)

Publication Number Publication Date
WO2002078672A2 WO2002078672A2 (en) 2002-10-10
WO2002078672A3 true WO2002078672A3 (en) 2003-03-20

Family

ID=26960351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009926 WO2002078672A2 (en) 2001-03-30 2002-03-29 Liposomal tumor necrosis factor compositions and methods

Country Status (1)

Country Link
WO (1) WO2002078672A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050090987A (en) * 2002-12-19 2005-09-14 알자 코포레이션 Method of treating angiogenic tissue growth
WO2015061206A2 (en) 2013-10-21 2015-04-30 North Carolina State University Methods and constructs for compound delivery

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338679A2 (en) * 1988-03-24 1989-10-25 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
EP0546951A1 (en) * 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
WO1999027908A1 (en) * 1997-12-04 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6043094A (en) * 1996-10-11 2000-03-28 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338679A2 (en) * 1988-03-24 1989-10-25 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
EP0546951A1 (en) * 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6043094A (en) * 1996-10-11 2000-03-28 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
WO1999027908A1 (en) * 1997-12-04 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines

Also Published As

Publication number Publication date
WO2002078672A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU7839198A (en) Method of laminate formation
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU5540586A (en) Non-surgical method for suppression of tumor growth
AU2212299A (en) Compositions and methods for the treatment of tumor
AU4657997A (en) Method for producing liposomes with increased percent of compound encapsulated
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU1273701A (en) Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001060319A3 (en) Polyhydroxylated benzene-containing compounds
AU5623398A (en) Methods of therapeutic administration of anti-cd40l compounds
AU2939897A (en) Administration of histamine for therapeutic purposes
AU2002246870A1 (en) Immunotherapeutic methods for extracorporeal modulation of cd36 and its ligands
WO2002078672A3 (en) Liposomal tumor necrosis factor compositions and methods
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002229106A1 (en) Semiconductor tiling structure and method of formation
AU3467099A (en) Methods for production of therapeutic cytokines
AU7350500A (en) Method and formula for tumor remission and suppression of cancer
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU3244495A (en) Methods of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine
AU2001278930A1 (en) Laminated rare earth structure and method of making
AU4281200A (en) Immuno-adjuvant pdt treatment of metastatic tumors
AU6617498A (en) Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemo- and radiotherapy
AU1744600A (en) Detection of t cell stimulating tumor antigens
WO2003018018A3 (en) Vinorelbine compositions and methods of use
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP